Why AbbVie Inc. (ABBV) is the Best Pharma Stock to Buy According to Hedge Funds
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
AbbVie Inc. (ABBV): A Magnificent Dividend Growth Stock to Invest In
We recently published a list of 10 Magnificent Dividend Growth Stocks to Invest In. In this article, we are going to take a ...
AbbVie (NYSE:ABBV) Urges Shareholders To Reject Proposals On Voting Rules And Human Rights Due Diligence
AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...
Rep. Jefferson Shreve Purchases Shares of AbbVie Inc. (NYSE:ABBV)
Representative Jefferson Shreve (R-Indiana) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on March ...
AbbVie Inc. stock outperforms competitors on strong trading day
AbbVie Inc. closed 0.64% short of its 52-week high of $215.66, which the company reached on March 4th.
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
AbbVie ABBV has outperformed the market over the past 10 years by 2.09% on an annualized basis producing an average annual return of 13.09%. Currently, AbbVie has a market capitalization of $360.27 ...